Radius Health (RDUS) Rating Lowered to Strong Sell at BidaskClub
Radius Health (NASDAQ:RDUS) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Tuesday.
Several other brokerages have also recently commented on RDUS. JPMorgan Chase & Co. decreased their target price on Radius Health from $60.00 to $59.00 and set a “$28.40” rating for the company in a research report on Monday, July 23rd. Bank of America decreased their target price on Radius Health from $51.00 to $47.00 and set a “buy” rating for the company in a research report on Wednesday, July 25th. Cowen reaffirmed a “hold” rating on shares of Radius Health in a research report on Tuesday, November 6th. Zacks Investment Research cut Radius Health from a “hold” rating to a “sell” rating in a research report on Tuesday, October 9th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $25.00 target price on shares of Radius Health in a research report on Tuesday, August 7th. Three research analysts have rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. Radius Health presently has an average rating of “Hold” and an average price target of $48.14.
Shares of RDUS traded up $0.21 during trading hours on Tuesday, hitting $15.22. 550,700 shares of the company were exchanged, compared to its average volume of 843,864. The firm has a market cap of $714.97 million, a PE ratio of -2.62 and a beta of 1.05. The company has a quick ratio of 5.39, a current ratio of 5.50 and a debt-to-equity ratio of 1.85. Radius Health has a one year low of $14.97 and a one year high of $41.16.
In other Radius Health news, major shareholder Growth N. V. Biotech bought 169,363 shares of the firm’s stock in a transaction dated Wednesday, August 15th. The stock was acquired at an average price of $20.83 per share, with a total value of $3,527,831.29. Following the completion of the transaction, the insider now directly owns 6,460,913 shares in the company, valued at approximately $134,580,817.79. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Growth N. V. Biotech bought 60,000 shares of the firm’s stock in a transaction dated Monday, August 20th. The stock was acquired at an average cost of $19.65 per share, with a total value of $1,179,000.00. Following the transaction, the insider now owns 6,590,276 shares of the company’s stock, valued at $129,498,923.40. The disclosure for this purchase can be found here. Company insiders own 3.42% of the company’s stock.
Several large investors have recently made changes to their positions in the stock. Raymond James & Associates raised its holdings in shares of Radius Health by 15.0% during the second quarter. Raymond James & Associates now owns 18,766 shares of the biopharmaceutical company’s stock worth $553,000 after acquiring an additional 2,449 shares in the last quarter. State of Wisconsin Investment Board raised its holdings in shares of Radius Health by 7.0% during the second quarter. State of Wisconsin Investment Board now owns 41,200 shares of the biopharmaceutical company’s stock worth $1,214,000 after acquiring an additional 2,700 shares in the last quarter. BTG Pactual Global Asset Management Ltd raised its holdings in shares of Radius Health by 30.5% during the second quarter. BTG Pactual Global Asset Management Ltd now owns 22,918 shares of the biopharmaceutical company’s stock worth $675,000 after acquiring an additional 5,356 shares in the last quarter. NumerixS Investment Technologies Inc purchased a new stake in shares of Radius Health during the second quarter worth $162,000. Finally, Xact Kapitalforvaltning AB purchased a new stake in shares of Radius Health during the first quarter worth $213,000.
About Radius Health
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.
Further Reading: Trading Strategy Methods for Individual Investors
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.